Glycomine Announces Completion of Enrollment in Global Phase 2b POLAR Study Evaluating GLM101 for PMM2-CDG
Glycomine, Inc. has announced the successful completion of patient enrollment in its Phase 2b POLAR clinical trial, a key milestone in the development of GLM101 for the treatment of Phosphomannomutase 2 congenital disorder of glycosylation (PMM2-CDG). This rare and debilitating inherited condition affects multiple organ systems and is characterized by significant neurological impairment, with no currently approved therapies available to patients.
The POLAR study is a global, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the safety and efficacy of GLM101, Glycomine’s investigational therapy. The completion of enrollment marks an important step forward in advancing potential treatment options for individuals living with PMM2-CDG, a disorder that imposes a substantial burden on patients, families, and caregivers.
PMM2-CDG is caused by mutations in the PMM2 gene, leading to defects in glycosylation, a critical biological process in which sugars are attached to proteins and lipids. This disruption affects numerous physiological systems, resulting in a wide spectrum of symptoms, including developmental delays, motor dysfunction, and organ abnormalities. Among these, ataxia—a neurological condition characterized by impaired coordination and balance—is one of the most common and debilitating manifestations, affecting more than 90% of patients. Ataxia significantly impacts mobility and daily functioning, making it a central focus of therapeutic development efforts.
The POLAR study has enrolled a total of 43 patients, including both pediatric and adult participants ranging in age from 4 to 47 years. The trial is being conducted across 15 clinical sites located in the United States, the United Kingdom, and multiple countries in Europe, reflecting a broad and diverse patient population. This international scope is particularly important for rare disease research, where patient populations are often geographically dispersed.
The primary objective of the POLAR study is to evaluate the effect of GLM101 on ataxia over a 24-week treatment period. The primary endpoint is measured using the International Cooperative Ataxia Rating Scale (ICARS), a widely recognized clinical tool used to assess the severity of ataxia and its impact on functional abilities. Improvements in ICARS scores would indicate a meaningful reduction in neurological impairment and an enhancement in patients’ quality of life.
In addition to the primary endpoint, the study includes several secondary efficacy measures designed to provide a comprehensive assessment of treatment impact. These include the Neuromuscular Gross Motor Outcome (GRO), which evaluates motor function; the Scale for the Assessment and Rating of Ataxia (SARA), another validated measure of ataxia severity; and both clinician- and patient-reported global impressions of change. Together, these endpoints aim to capture both objective and subjective aspects of disease progression and treatment response.
The initiation and completion of enrollment in the POLAR study build upon encouraging findings from Glycomine’s earlier Phase 2a clinical trial of GLM101. In that open-label study, the investigational therapy demonstrated meaningful improvements in ataxia and other clinical outcomes, along with a favorable safety profile. These results provided the scientific rationale for advancing GLM101 into a larger, more rigorous Phase 2b trial.
Dr. Rose Marino, Chief Medical Officer of Glycomine, highlighted the importance of this milestone, noting that the POLAR study represents a critical step in validating the therapeutic potential of GLM101. She emphasized that the trial is designed to confirm and expand upon the positive signals observed in the Phase 2a study, with the goal of delivering a much-needed treatment option for patients with PMM2-CDG.
Dr. Marino also expressed gratitude to the patients, families, caregivers, and clinical investigators who have contributed to the success of the study. Participation in rare disease trials often requires significant commitment and collaboration, and the completion of enrollment reflects the dedication of the global PMM2-CDG community.
Looking ahead, Glycomine anticipates reporting topline data from the POLAR study in the fourth quarter of 2026. These results will be closely watched by the medical and scientific communities, as they have the potential to inform future regulatory submissions and guide the next مراحل of clinical development. Positive outcomes could represent a major breakthrough for a patient population that currently lacks effective treatment options.
In parallel with the ongoing Phase 2b trial, Glycomine plans to present additional data from its completed Phase 2a study at multiple scientific conferences throughout 2026. These presentations are expected to provide further insights into the mechanism of action, efficacy, and safety profile of GLM101, contributing to a growing body of evidence supporting its development.
The advancement of GLM101 also highlights broader trends in rare disease research, where increased understanding of genetic and molecular mechanisms is driving the development of targeted therapies. Innovations in clinical trial design, including global collaboration and the use of validated outcome measures, are enabling more efficient evaluation of potential treatments in small patient populations.
For individuals living with PMM2-CDG, the progress of the POLAR study offers a sense of hope. The lack of approved therapies has long been a significant unmet need, leaving patients and families with limited options for managing the disease. The development of GLM101 represents a promising خطوة toward addressing this gap and improving outcomes for those affected by this challenging condition.
In conclusion, the completion of enrollment in the Phase 2b POLAR study marks a significant milestone for Glycomine and the PMM2-CDG community. By advancing GLM101 through rigorous clinical evaluation, the company is working to bring a potential new therapy closer to reality. As the study progresses and data become available, the results will play a crucial role in determining the future of this investigational treatment and its potential to transform the lives of patients living with PMM2-CDG.
About PMM2-CDG
Phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG), previously known as CDG-1a, is the most common congenital disorder of glycosylation. PMM2-CDG has an incidence of 1 in 30,000 to 40,000, affecting approximately 14,000 people in the United States and Europe and as many as 50,000 patients world-wide. PMM2-CDG is caused by reduced activity of the phosphomannomutase 2 enzyme, resulting in a deficiency of mannose-1-phosphate and disruption of N-glycosylation. PMM2-CDG results in a wide array of neurological and peripheral clinical symptoms, which can be severe and life-threatening. Ataxia is a core clinical feature of the disorder, affecting more than 90% of patients and is a key driver of disease burden.
About GLM101
Glycomine’s lead investigational drug candidate GLM101 is a liposomal mannose-1-phosphate substrate replacement therapy in development to treat PMM2-CDG. GLM101 is administered via a weekly IV infusion to address deficient glycosylation in both the central nervous system and periphery. GLM101 has received Orphan Drug Designation in the U.S. and E.U. and Rare Pediatric Disease Designation and Fast Track Designation in the U.S. GLM101 has previously been tested in a Phase 1 healthy volunteers study and a Phase 2a open-label study in PMM2-CDG (ClinicalTrials.gov Identifier: NCT05549219).
About Glycomine, Inc.
Glycomine is a clinical-stage biotechnology company that is advancing treatments for serious rare diseases with no other therapeutic options. The company is based in San Carlos, California, and supported by leading international life sciences investors.
Source Link:https://www.businesswire.com/
